Special Issue on Molecular Target in CNS Malignancies

Submission Deadline: Feb. 25, 2020

Please click the link to know more about Manuscript Preparation: http://www.cnnjournal.org/submission

This special issue currently is open for paper submission and guest editor application.

Please download to know all details of the Special Issue

Special Issue Flyer (PDF)
  • Lead Guest Editor
    • Mingzhi Han
      University of Bergen, Bergen, Norway
  • Guest Editor
    Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to complete the Guest Editor application.
    • Shuai Wang
      Shandong University, Jinan, China
    • Wenbo Zhao
      Shandong University, Jinan, China
    • Bin Huang
      Shandong University, Jinan, China
    • Ya Zhang
      Shandong University, Jinan, China
    • Yang Kong
      Shandong University, Jinan, China
    • Yuzhen Wei
      Jining Hospital, Jinan, China
  • Introduction

    Human gliomas are the most common and deadly type of primary intracranial tumors and account for approximately 80% of all primary CNS malignancies. Gliomas are histopathologically classified into four tumor grades (I–IV) according to the World Health Organization (WHO). WHO grade IV or glioblastoma multiforme (GBM) confers the worst prognosis, with a median survival time of merely 12 to 15 months following primary diagnosis.
    With advancement of gene technology, molecular signatures have become prominent in the classification of gliomas in recent years. Whole-genome analysis of patient cases through The Cancer Genome Atlas (TCGA), revealed a molecular classification scheme for GBM which includes four molecular subtypes: proneural, neural, classical, and mesenchymal. Among these four subtypes, the mesenchymal subtype was distinguished from the others as being particularly aggressive. Thus, there is an urgent need for the exploration of novel biomarkers and therapeutic targets for brain tumor, especially GBM.
    The special issue “Molecular Target in CNS malignancies” aims to highlight the significant findings and advances in our understanding of the role of the novel molecular targets, diagnostic biomarkers as well as novel prognostic indicators in CNS malignancies, especially GBM.
    The special issue “Molecular Target in CNS malignancies” will provide an important forum for exciting findings in Neuro-oncology-related research, presenting an unparalleled opportunity to communicate information to specialists and the public, opening new avenues for the understanding, prevention, diagnosis and treatment of brain tumor patients.

    Aims and Scope:

    1. Molecular targeted therapies
    2. Prognostic indicators of CNS malignancies
    3. Clinical trials and pre-clinical studies of neuro-oncology
    4. Cancer antigens and immune checkpoint
    5. Molecular mechanisms of drug resistance in CNS malignancies
    6. RNA-seq and proteomics study of CNS malignancies

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.cnnjournal.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.

  • Published Papers

    The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.